ROS1 and neoplasm: NGS is primarily applied in advanced non-squamous NSCLC, where tumor NGS testing is routinely recommended owing to the presence of numerous actionable genetic alterations, including EGFR, ALK, and ROS1, which can be targeted with specific therapies.